| Contact | Eligibility | Links |
|---|---|---|
 Chris McKinlay 0274725099 Lisa Mravicich 021430564 | Inclusion: *34 to 36 weeks (must be <72 hours at randomisation) Exclusion: *Major congenital malformation(s) *Minor congenital abnormality affecting respiration, growth, or development *Previous caffeine *Renal or hepatic impairment *Tachyarrhythmia *Seizures *Hypoxic ischaemic encephalopathy *Mother <16 years | Nursing Guide Screen & Randomise Trial Data PISC Parent Brochure Protocol |
 Neurologist 096316128 Chris McKinlay 0274725099 | PHASE 2 COMPLETED!! Recruitment paused pending Phase 3 approval Screening: In the following infants, start EEG, provide parent flyer and notify the study team: *HIE stage 2 or 3 *Any therapeutic hypothermia *Other encephalopathy, including meningitis *Suspected seizure, including unexplained apnoea *Moderate to severe metabolic acidosis (pH<7.0, base excess >12 mmol/L) at risk of encephalopathy (discuss with SMO if EEG appropriate) Inclusion: *≥35 weeks *>2.2 kg *Electrographic seizures (<8 minutes/hour) Exclusion: *Imminent death Use of AED before enrolment: If anti-seizure medication is required before enrolment, use IV midazolam (150 micrograms/kg). If sedation is required, use morphine rather than midazolam. | Nursing Guide Parent Flyer PISC PK Sample Documentation Form PK Sample Lab Form Parent Feedback Form Parent Discharge Information |
 Lisa Mravicich 021430564 | Inclusion: *<32 weeks or <1500 g *Dry blood spot TSH above the screening threshold Exclusions: *Triplets *Maternal thyroid disease requiring treatment with thyroxine, carbimazole or propylthiouracil Known or strongly suspected syndromes with known thyroid abnormalities, e.g., Down syndrome *Suspected or confirmed pituitary abnormalities *Major congenital anomalies, receiving palliative care or critically unwell | PIS Cases PIS Controls Protocol Assessments |
 | COMING SOON!! | Website PLATIPUS Video BabyCCINO Video Spinnaker |
DM2 CGM  Lisa Mravicich 021430564 | RECRUITMENT COMPLETED!! Inclusion: *32+weeks’ gestation *Type 2 Diabetes Mellitus *Singleton pregnancy | Screen Trial Data PISC |
 | RECRUITMENT COMPLETED!! Follow-up continues until 2027 Inclusion: *<32 weeks *Singleton pregnancy *Severe FGR: AC ≤3rd centile for gestational age OR AC <10th centile and ≥1 abnormal fetoplacental Doppler (a: Uterine artery pulsatility index ≥95th centile or b: Umbilical artery pulsatility index ≥95th centile or absent/reversed end-diastolic flow) Exclusion: *Known fetal chromosomal or major structural anomaly, or non-placental cause of FGR *Immediate delivery indicated, e.g., absent A wave in ductus venosus, preterminal CTG or biophysical profile *Co-recruitment in another clinical trial where a pharmaceutical product or nutritional supplement impacting on oxidative stress is the trial intervention *Currently prescribed Fluvoxamine | Screen Randomise Trial Data Patient Video Parent Brochure PISC Poster Protocol |
 | 3,923 INFANTS RECRUITED!! 1-year follow-up completed 6-year follow-up continues until December 2028. Inclusion: *≥32 weeks *<8 weeks old Exclusion: *Previous exposure to paracetamol or ibuprofen *Chronic disease associated with limited life expectancy (<6 years) *Likely to leave NZ in first 6 years | Databases Parent Video Protocol Website |
 | RECRUITMENT COMPLETED!! Early childhood follow-up continues until 2026. Inclusion: *<28 weeks *<48 hours *Surfactant, if given, <12 hours ago *Receiving mechanical ventilation via an endotracheal tube OR receiving non-invasive respiratory support including CPAP, nasal IPPV or nasal high flow AND a clinical decision to treat with exogenous surfactant Exclusion: *Previous steroids for prevention of lung disease (steroids for hypotension is OK) *Infant is considered non-viable *Major congenital anomaly that is likely to affect respiratory status *Severe pulmonary hypoplasia following PPROM with severe oligo/anhydramnios, where the clinician, based on clinical assessment on the first postnatal day, believes survival is unlikely *More than one dose of previous surfactant | Trial Data |
 | RECRUITEMENT COMPLETED!! Follow-up continues until December 2026 Inclusion: *<29 weeks *Within 6 hours of blood culture taken for suspected LOS (>48 hours of age) or NEC. Exclusion: *Major congenital malformation(s) or chromosomal abnormalities. Commence the study infusion within 6 hours of a blood culture being taken for EVERY episode of suspected LOS or NEC for the ENTIRE hospital stay. *Infuse for 12 hours on days 1-2. *Infuse for 6 hours on days 3-6 if proven LOS/NEC or probable LOS (antibiotics for ≥5 days AND raised CRP) | |
Current Studies
